会计年度:2011-12-31收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 医药制造业 | 400,680,700.00 | 96,151,000.00 | 304,529,700.00 | 76.00 |
|
会计年度:2011-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 八支装四磨汤口服液 | 70,305,500.00 | 13,489,900.00 | 56,815,600.00 | 80.81 |
| 六支装四磨汤口服液 | 4,914,200.00 | 944,800.00 | 3,969,400.00 | 80.77 |
| 其他 | 14,086,100.00 | 11,253,300.00 | 2,832,800.00 | 20.11 |
| 其中：固体口服制剂 | 6,233,800.00 | 4,231,400.00 | 2,002,400.00 | 32.12 |
| 其中:液体口服制剂 | 1,231,000.00 | 1,267,400.00 | -36,400.00 | -2.96 |
| 其中:注射剂 | 6,621,200.00 | 5,754,600.00 | 866,600.00 | 13.09 |
| 十支装四磨汤口服液 | 48,376,900.00 | 9,161,800.00 | 39,215,100.00 | 81.06 |
| 缩泉胶囊 | 14,102,000.00 | 2,227,800.00 | 11,874,200.00 | 84.20 |
| 银杏叶胶囊 | 14,244,100.00 | 3,192,600.00 | 11,051,500.00 | 77.59 |
| 愈伤灵胶囊 | 9,671,700.00 | 2,480,600.00 | 7,191,100.00 | 74.35 |
|
会计年度:2010-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 十支装四磨汤口服液 | 91,825,469.90 | 17,150,051.02 | -- | -- |
| 10.注射剂 | 12,636,362.09 | 10,466,664.73 | -- | -- |
| 1合计 | 343,414,849.29 | 80,658,713.31 | -- | -- |
| 八支装四磨汤口服液 | 141,182,497.67 | 26,898,115.31 | -- | -- |
| 六支装四磨汤口服液 | 7,617,732.97 | 1,527,015.63 | -- | -- |
| 愈伤灵胶囊 | 25,734,561.64 | 5,698,718.85 | -- | -- |
| 银杏叶胶囊 | 23,588,181.64 | 5,202,060.24 | -- | -- |
| 6.缩泉胶囊 | 26,400,173.89 | 3,518,862.46 | -- | -- |
| 7.其他 | 27,066,231.58 | 20,663,889.80 | -- | -- |
| 8.其中:固体口服制剂 | 12,451,248.05 | 8,217,699.21 | -- | -- |
| 9.液体口服制剂 | 1,978,621.44 | 1,979,525.86 | -- | -- |
| 八支装四磨汤口服液 | 141,182,497.67 | 26,898,115.31 | 114,284,382.36 | -- |
| 固体口服制剂 | 12,451,248.05 | 8,217,699.21 | 4,233,548.84 | -- |
| 六支装四磨汤口服液 | 7,617,732.97 | 1,527,015.63 | 6,090,717.34 | -- |
| 十支装四磨汤口服液 | 91,825,469.90 | 17,150,051.02 | 74,675,418.88 | -- |
| 缩泉胶囊 | 26,400,173.89 | 3,518,862.46 | 22,881,311.43 | -- |
| 液体口服制剂 | 1,978,621.44 | 1,979,525.86 | -904.42 | -- |
| 银杏叶胶囊 | 23,588,181.64 | 5,202,060.24 | 18,386,121.40 | -- |
| 愈伤灵胶囊 | 25,734,561.64 | 5,698,718.85 | 20,035,842.79 | -- |
| 注射剂 | 12,636,362.09 | 10,466,664.73 | 2,169,697.36 | -- |
|
会计年度:2010-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 八支装四磨汤口服液 | 59,099,500.00 | 11,383,000.00 | 47,716,500.00 | 80.74 |
| 六支装四磨汤口服液 | 3,944,400.00 | 797,400.00 | 3,147,000.00 | 79.78 |
| 其他 | 24,960,400.00 | 11,973,100.00 | 12,987,300.00 | 52.03 |
| 其中:固体口服制剂 | 18,004,800.00 | 6,073,000.00 | 11,931,800.00 | 66.27 |
| 其中:液体口服制剂 | 1,357,400.00 | 1,367,500.00 | -10,100.00 | -0.74 |
| 其中:注射剂 | 5,598,200.00 | 4,532,600.00 | 1,065,600.00 | 19.03 |
| 十支装四磨汤口服液 | 41,394,200.00 | 7,748,300.00 | 33,645,900.00 | 81.28 |
| 银杏叶胶囊 | 10,118,100.00 | 2,251,000.00 | 7,867,100.00 | 77.75 |
| 愈伤灵胶囊 | 11,668,500.00 | 2,095,600.00 | 9,572,900.00 | 82.04 |
|
5/5 转到 
